These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 33163564)

  • 41. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
    Antonini A; Abbruzzese G; Berardelli A; Modugno N; Stroppa I; Tamma F; Sensi M; Mancini F; Cossu G; Stefani A; Tambasco N; Tessitore A; Fabbrini G; Pontieri FE; Solla P; Bentivoglio AR; Comi C; Minafra B; Riboldazzi G; Melchionda D; Martino T; Lopiano L
    J Neural Transm (Vienna); 2020 Jun; 127(6):881-891. PubMed ID: 32212015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease.
    Murata M; Mihara M; Hasegawa K; Jeon B; Tsai CH; Nishikawa N; Oeda T; Yokoyama M; Robieson WZ; Chatamra K; Facheris MF; Benesh J
    Ther Adv Neurol Disord; 2018; 11():1756286418759315. PubMed ID: 29511383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What can we learn from the effect of trihexyphenidyl on motor fluctuations during continuous levodopa-carbidopa intestinal gel infusion (LCIG)? - First documented case.
    Kubo SI; Nakamura K; Tada Y; Kashio N; Yamashita S
    Clin Park Relat Disord; 2020; 3():100071. PubMed ID: 34316650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M; Antonelli F; Cámara A; Puente V; de Fabregues-Nebot O; Hernandez-Vara J; Calopa M; Pascual-Sedano B; Campolongo A; Valldeoriola F; Tolosa E; Kulisevsky J; Martí MJ
    Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.
    Standaert DG; Aldred J; Anca-Herschkovitsch M; Bourgeois P; Cubo E; Davis TL; Iansek R; Kovács N; Pontieri FE; Siddiqui MS; Simu M; Bergmann L; Kukreja P; Robieson WZ; Chaudhuri KR
    Mov Disord Clin Pract; 2021 Oct; 8(7):1061-1074. PubMed ID: 34631942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
    Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
    Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience.
    Gültekin M; Ulukan Ç; Tezcan S; Doğu O; Hanağasi H; Bilgiç B; Bora Tokçaer A; Çakmur R; Elibol B; Mirza M; İnce Günal D; Erer Özbek ÇS; Kenangil G; Yilmaz Küsbeci Ö; Akbostanci MC
    Turk J Med Sci; 2020 Feb; 50(1):66-85. PubMed ID: 31731332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
    Othman AA; Dutta S
    Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience.
    Szász JA; Constantin VA; Orbán-Kis K; Bancu LA; Bataga SM; Ciorba M; Nagy E; Neagoe MR; Mihály I; Szász RM; Kelemen K; Simu M; Szatmári S
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE.
    Aldred J; Anca-Herschkovitsch M; Antonini A; Bajenaru O; Bergmann L; Bourgeois P; Cubo E; Davis TL; Iansek R; Kovács N; Kukreja P; Onuk K; Pontieri FE; Robieson W; Siddiqui MS; Simu M; Standaert DG; Chaudhuri KR
    Neurodegener Dis Manag; 2020 Oct; 10(5):309-323. PubMed ID: 32873195
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
    Kulisevsky J; Bejr-Kasem H; Martinez-Horta S; Horta-Barba A; Pascual-Sedano B; Campolongo A; Marín-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Izquierdo-Barrionuevo C; de Fàbregues O; Puente V; Crespo-Cuevas A; Calopa M; Pagonabarraga J
    J Neurol; 2020 Nov; 267(11):3400-3410. PubMed ID: 32607644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
    Fernández-Rodríguez B; Dupouy J; Harroch E; Fabre-Delcros MH; Barthélémy C; Loubière P; Barange K; Brefel-Courbon C; Rascol O; Ory-Magne F
    Rev Neurol (Paris); 2021 Oct; 177(8):919-923. PubMed ID: 34154827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait].
    Okajima M; Fujioka S; Komorita S; Nishida A; Mishima T; Tsuboi Y
    Rinsho Shinkeigaku; 2021 Jun; 61(6):398-400. PubMed ID: 34011807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy].
    Nakano T; Hirozawa D; Shimamura M; Sasaki T; Ikenaka K; Mochizuki H
    Rinsho Shinkeigaku; 2018 Sep; 58(9):570-573. PubMed ID: 30175807
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
    Olanow CW; Kieburtz K; Odin P; Espay AJ; Standaert DG; Fernandez HH; Vanagunas A; Othman AA; Widnell KL; Robieson WZ; Pritchett Y; Chatamra K; Benesh J; Lenz RA; Antonini A;
    Lancet Neurol; 2014 Feb; 13(2):141-9. PubMed ID: 24361112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.